drugset / Trial / NCT00631722
Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of Schizophrenia
RandomizedParallel-groupOpen-labelTreatment
Summary
This study attempts to observe the efficacy (response time) and safety of the second-generation antipsychotic agent-quetiapine versus the first-generation antipsychotic agent-haloperidol, in treating acute schizophrenia episode and to evaluate the effect of the effectiveness of acute schizophrenia episode on long-term tolerability.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-01
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Haloperidol | Other / unclassified | 12 mg | — |
| Comparator | Haloperidol | Other / unclassified | 20 mg | — |
| Subject | Quetiapine | Small molecule | 600 mg | — |
| Subject | Quetiapine | Small molecule | 750 mg | — |